Pay in 4 interest-free payments of $6.08 Learn more
Ships within 48 hours · Estimated delivery Sep 1 - Sep 6
In a phase 2 clinical trial targeting obese individuals without type 2 diabetes (T2D), retatrutide dosed at 1 to 12 mg resulted in up to 24.2% weight loss over a 48-week treatment period, compared to 2.1% in the placebo group, and demonstrated a dose-dependent effect
Because the compound preserves the pulsatile pattern of endogenous GHRH signalling, the resulting GH release retains the natural cadence rather than the flat profile that follows direct exogenous GH administration
Res (2018) 16:26
In vitro cellular signaling experiments
Liraglutide in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
Interesting Finding: Reduced Alcohol Cravings Interestingly, recent research has found that GLP-1 medications may actually reduce alcohol cravings and consumption in some individuals: Studies have shown that both semaglutide (GLP-1 agonist) and tirzepatide (GLP-1/GIP combination) appear to effectively reduce alcohol consumption in individuals with obesity
